Glutathione S-transferases as risk factors in prostate cancer

Autrup, Judith L.; Thomassen, Lars; Olsen, Jennifer; Wolf, Holly J.; Autrup, Herman

doi:10.1097/00008469-199912000-00008

Cited by 63 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This frequency is nearly similar to the frequencies found in other studies that analyzed GSTP1 polymorphism. 12,33,36,37 38 Harries et al 27 and KoteJarai et al 19 that GSTP1 Ile/Ile is protective against development of PCa. Two other studies found that, the GSTP1 Ile/Ile genotype has been positively associated with PCa.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Glutathione S-transferase gene polymorphisms (GSTM1, GSTT1, GSTP1) and prostate cancer: a case-control study in Tehran, Iran

Safarinejad¹,

Shafiei²,

Safarinejad³

2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

We evaluated the relationship between polymorphisms in the glutathione S-transferases (GSTs) GSTM1, GSTT1 and GSTP1 genes and prostate cancer (PCa). PCR-restriction fragment length polymorphism assay was used to genotype the GSTM1, GSTT1, and GSTP1 polymorphisms in 168 PCa cases and 336 frequency matched controls. The GSTM1 null, and GSTT1 null genotypes were associated with an increased odds ratio (OR) for PCa (OR ¼ 3.28, 95% confidence interval (CI): 2.47-5.64; P ¼ 0.005, and OR ¼ 3.21, 95% CI: 2.52-5.64; P ¼ 0.005, respectively) (Pcorrected ¼ 0.0062). The frequency of GSTP1 Val/Val genotype was 14.3% in cases compared with 2.4% in controls, this polymorphism thus being associated with a significantly increased risk of PCa (OR ¼ 3.72, 95% CI: 1.67-5.65; P ¼ 0.002). The risk associated with the concurrent absence of both of the genes (OR ¼ 4.8, 95% CI: 2.34-6.78) was greater than the product of risk in men with either null (OR ¼ 1.52, 95% CI: 0.82-2.31) genotype combinations (P ¼ 0.001, Pcorrected ¼ 0.0045). The combination of GSTP1 Ile/Val or Val/Val polymorphism with the GSTT1 null and GSTM1 null type resulted in an OR of 6.21 (95% CI: 4.83-16.87) (P ¼ 0.0001, Pcorrected ¼ 0.0062). A higher frequency of the GSTM1 null genotype and GSTT1 null genotype was observed in patients with Gleason score 47, with an OR for GSTM1 null 4.67 (95% CI: 3.64-7.62; P ¼ 0.001) and with an OR for GSTT1 null 3.62 (95% CI: 2.31-5.74; P ¼ 0.004). The results obtained demonstrated that simultaneous presence of three potentially risk alleles (GSTM1 null, GSTT1 null and GSTP1 Val) lead to a significant OR increase for PCa.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Two other studies found that, the GSTP1 Ile/Ile genotype has been positively associated with PCa. 22,36 Mao et al examined the possible effect modification by the GSTP1 polymorphism on smoking and PCa. They found that in individuals with the Ile/Ile genotype, smoking was strongly associated with an increased risk of PCa.…”

Section: Discussionmentioning

confidence: 99%

Glutathione S-transferase gene polymorphisms (GSTM1, GSTT1, GSTP1) and prostate cancer: a case-control study in Tehran, Iran

Safarinejad¹,

Shafiei²,

Safarinejad³

2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…An A to G transition at nucleotide 313 in exon 5 of the GSTP1 gene, which replaces isoleucine (Ile) at codon 105 with valine (Val) within the active site of the enzyme, is associated with reduced enzymatic activity for certain substrates and altered thermostability [20,21]. While some studies have found an association between prostate cancer and the codon 105 variant Val allele of GSTP1 (Val 105 ) [22][23][24], others have failed to find an association [25][26][27][28]. Moreover, a recent meta-analysis of prostate cancer association studies involving the GSTP1 Ile105Val polymorphism calculated an overall odds ratio of 1.05 for the GSTP1 Val 105 allele [29].…”

Section: Introductionmentioning

confidence: 99%

Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism

Rybicki

Neslund‐Dudas

Nock

et al. 2006

Cancer Detection and Prevention

View full text Add to dashboard Cite

Condensed Abstract-Men who carry the GSTP1 Val 105 variant who are exposed at high levels to occupational PAH are at increased risk for prostate cancer. This increased risk is more pronounced in men under age 60 or with a family history of prostate cancer.Background-Variation in the glutathione S-transferase (GSTP1) gene and occupational polycyclic aromatic hydrocarbons (PAH) exposure are putative prostate cancer risk factors. An Ile/ Val polymorphism in codon 105 of GSTP1 affects its enzymatic activity toward PAH detoxification, a possible mechanism in prostate carcinogenesis.

show abstract

“…Two studies of predominantly Caucasian population suggested a modestly elevated risk (OR ¼ 1.83 (1.19 -2.80)) 30 (OR ¼ 2.31 (1.17 -4.59)), 25 while three others failed to confirm these results. 21,22,33 No relationship between GSTT1 genotype and prostate cancer risk was found in a study of Japanese men. 34 …”

Section: Gstt1mentioning

confidence: 98%

Polymorphisms of GSTP1 and related genes and prostate cancer risk

Beer

Evans

Hough

et al. 2002

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Glutathione S-transferase P1 (GSTP1) is markedly downregulated in prostate cancer and prostatic intraepithelial neoplasia compared to normal prostate tissue. Downregulation of GSTP1 may, therefore, be an early event in prostate carcinogenesis. An A?G polymorphism at nucleotide 313 results in an amino acid substitution (Ile105Val) in the substrate binding site of GSTP1 and reduces catalytic activity of GSTP1. In a study of 36 prostate cancer patients, Harries et al. reported that the Ile/Ile genotype is associated with a decreased risk of prostate cancer (odds ratio 0.4 (0.17 -0.82)). We sought to confirm this finding and to examine the impact of this polymorphism together with several related polymorphisms implicated as risk factors for carcinogen-associated malignancies. One hundred and seventeen patients with prostate adenocarcinoma and 183 population-based controls were recruited to this case -control study. Genotyping of the GSTP1 (Ile105Val), GSTM1 (null), GSTT1 (null) and CYP1A1 (Ile462Val) genes was performed using polymerase chain reaction (PCR) based techniques on DNA prepared from peripheral blood. A questionnaire was used to collect demographic information from each subject. Cases were significantly older (P < 0.0001) and had significantly greater family history of prostate cancer (P < 0.0001), confirming known risk factors for this disease. By w 2 analysis, none of the genotype distributions varied among cases and controls. Using a logistic regression model to control for known risk factors we were also unable to demonstrate a significant association with prostate cancer for any of the polymorphisms tested. This population fails to identify a relationship between the above polymorphisms and prostate adenocarcinoma.

show abstract

Glutathione S-transferases as risk factors in prostate cancer

Cited by 63 publications

References 0 publications

Glutathione S-transferase gene polymorphisms (GSTM1, GSTT1, GSTP1) and prostate cancer: a case-control study in Tehran, Iran

Glutathione S-transferase gene polymorphisms (GSTM1, GSTT1, GSTP1) and prostate cancer: a case-control study in Tehran, Iran

Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism

Polymorphisms of GSTP1 and related genes and prostate cancer risk

Contact Info

Product

Resources

About